Baseline cytogenetic studies at diagnosis remain the single most important determinant of
outcome in patients with acute myeloid leukemia (AML). However, the prognostic role of the …

Karyotypic analysis at time of diagnosis has an important value in determining initial
response to treatment, remission duration and overall survival (OS) in acute myeloid …

This study aimed to analyze the factors associated with outcomes of bone marrow
transplantation (UR-BMT) or cord blood stem cell transplantation from unrelated donors (UR …

Autologous stem cell transplantation remains a clinical option to consolidate some adult
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …

Background Allogeneic hematopoietic cell transplantation (allo-HCT) using a mismatched
unrelated donor (MMUD) and cord blood transplantation (CBT) are valid alternatives for …

Background: So called triple-negative acute myeloid leukemias (AML) form a
heterogeneous subgroup of intermediate-risk AML according to ELN criteria. Molecularly …

Background/Aim: For intermediate risk acute myeloid leukemia patients, allogeneic
hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally …

In the absence of a fully matched donor, adult patients with Acute Leukemia (AML and ALL)
in CR are nowadays usually offered, as a first choice, an allogeneic transplant from an …

Introduction: In a previous report, we found that post-transplant clinical outcomes were not
significantly different between MAC (BuCy, CyTBI) and RIC (FluBu2TBI400) groups in AML …

Background: Favorable acute myelogenous leukemia (AML) includes AML with t (8: 21), inv
(16), and those with NPM1 without FLT3-ITD without adverse cytogenetics (ELN 2022). The …